JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2007; 49:1772-1780, doi:10.1016/j.jacc.2006.12.048 (Published online 13 April 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Committee Members and Investigators
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (35)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erdmann, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Erdmann, E.
Related Collections
Right arrowRelated Article

The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction

Results From the PROactive (PROactive 05) Study

Erland Erdmann, MD, FESC, FACC*,1,*, John A. Dormandy, FRCS, DSc{dagger},1, Bernard Charbonnel, MD{ddagger},1, Massimo Massi-Benedetti, MD§,1, Ian K. Moules, BSc (Hons)||,2, Allan M. Skene, PhD,3 on behalf of the PROactive Investigators

* Medizinische Klinik III der Universität zu Köln, Köln, Germany
{dagger} St. George’s Hospital, London, United Kingdom
{ddagger} Clinique d’Endocrinologie, Hôtel Dieu, Nantes, France
§ University of Perugia, Medicine and Metabolic Diseases, Perugia, Italy
|| Takeda Global Research and Development Centre (Europe) Ltd., London, United Kingdom
Nottingham Clinical Research Ltd., Nottingham, United Kingdom.


Figure 1
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1 Time to Fatal/Nonfatal MI (Excluding Silent MI)

Kaplan-Meier curve of the time to fatal/nonfatal myocardial infarction (MI) (excluding silent MI). The solid line represents the pioglitazone group; the dashed line represents the placebo group. CI = confidence interval; HR = hazard ratio.

 

Figure 2
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2 Time to Nonfatal MI (Excluding Silent MI), Coronary Revascularization, Acute Coronary Syndrome, or Cardiac Death (Composite Cardiac End Point)

Kaplan-Meier curve of the time to nonfatal MI (excluding silent MI), coronary revascularization, acute coronary syndrome, or cardiac death (composite cardiac end point). The solid line represents the pioglitazone group; the dashed line represents the placebo group. Abbreviations as in Figure 1.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2007 by the American College of Cardiology Foundation.